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Nuclear factor, erythroid 2-like 2 (Nrf2) is a transcription factor that has been gaining attention in the ﬁeld of
pharmacology and especially in the chemoprevention of diseases such as cancer, metabolic and neurodegen-
erative diseases, etc. This is because natural compounds such as sulforaphane, which is found in broccoli sprout
extracts, can activate Nrf2. The repertoire of the roles of Nrf2 is ever increasing; besides its traditional anti-
oxidant and cytoprotective eﬀects, Nrf2 can have other functions as a transcription factor. We have recently
shown that Nrf2 directly regulates the expression of thyroglobulin (Tg), which is the most abundant thyroidal
protein and the precursor of thyroid hormones. Two functional binding sites for Nrf2 (antioxidant response
elements, AREs) were identiﬁed in the regulatory region of the TG gene. Interestingly, we then observed that one
of these AREs harbors a rare single-nucleotide polymorphism (SNP). Also recently, we performed the ﬁrst
genome-wide association study (GWAS) for common SNPs that impact the circulating levels of Tg. Based on
these investigations, we were triggered (i) to investigate whether common SNPs in the Nrf2 pathway correlate
with circulating Tg levels; and (ii) to examine whether the rare SNP in one of the TG regulatory AREs may aﬀect
gene expression. To address the ﬁrst question, we analyzed GWAS data from a general population and its two
subpopulations, one with thyroid disease and/or abnormal thyroid function tests and the other without, in which
circulating Tg levels had been measured. Statistically signiﬁcant associations with Tg levels were observed in the
genes encoding Nrf2 and Keap1, including, notably, a known functional SNP in the promoter of the gene en-
coding Nrf2. Regarding the rare SNP (rs778940395) in the proximal ARE of the TG enhancer, luciferase reporter
gene expression studies in PCCL3 rat thyroid follicular cells showed that this SNP abrogated the basal and
sulforaphane- or TSH-induced luciferase activity, behaving as a complete loss-of-function mutation. Thus, both
rare and common genetic variation in the Keap1/Nrf2 pathway can impact TG expression and Tg circulating
levels, respectively.
1. Introduction
The transcription factor nuclear factor, erythroid 2 (NFE2)-like 2
(Nfe2l2), also known as NFE2-related factor 2 (Nrf2), lies central to the
regulation of a battery of antioxidant, cytoprotective and tissue-speciﬁc
homeostatic genes [1]. Under basal conditions, Nrf2 is mainly
sequestered in the cytoplasm by kelch-like ECH-associated protein 1
(Keap1), a protein tethered to the actin cytoskeleton that serves as an
adaptor facilitating the ubiquitination of Nrf2 by cullin 3 (Cul3); poly-
ubiquitinated Nrf2 is subsequently degraded by the proteasome [2].
Keap1 is a protein rich in cysteine residues, whose sulfhydryl groups act
as “sensors” for oxidative or electrophilic stimuli as they react with
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electrophilic or oxidative substances. These sulfhydryl groups also react
with natural or synthetic activators of the Nrf2 pathway, including the
so-called indirect antioxidants [3], leading to conformational changes
in Keap1 that render it unable to present Nrf2 molecules to Cul3. Thus,
de novo synthesized Nrf2 escapes Keap1/Cul3-mediated proteasomal
degradation, and it accumulates the nucleus where it regulates (mainly,
stimulates) the expression of its target genes by binding to antioxidant
response element (ARE; 5′-NTGAG/CNNNGC-3′) sequences in their
regulatory regions [4].
One of the many natural compounds that can activate the Keap1/
Nrf2 pathway is sulforaphane (1-Isothiocyanato-4-(methylsulﬁnyl)bu-
tane). This indirect antioxidant belongs to the group of isothiocyanates
and is derived mainly from cruciferous vegetables like broccoli sprouts.
These vegetables actually contain glucoraphanin, the precursor of sul-
foraphane, which is converted to active sulforaphane by the enzyme
myrosinase that is present in some plants as well as in the human in-
testinal microﬂora [5]. Sulforaphane has already been used in clinical
trials with promising results in a variety of clinical settings (cancer,
diabetes, skin disorders, heart disease, respiratory diseases, psychiatric
diseases) [6]. It is believed that the beneﬁcial eﬀect of Nrf2 pathway
activation by sulforaphane is not mediated only by the induction of an
antioxidant/cytoprotective response but also through other pathways
that Nrf2 can regulate in its capacity of transcription factor. For in-
stance, in the case of diabetes, induction of Nrf2 pathway by sulfor-
aphane can repress gluconeogenesis [7]. Hence, in view of the growing
interest in antioxidants as Nrf2 pathway activators, research is also
warranted not only to evaluate their eﬀectiveness but also to identify
the proper dosing regimens, and ideally also to predict and prevent
adverse eﬀects based on the known eﬀects of Nrf2 on tissue-speciﬁc
homeostasis [8]. In this context, we recently investigated the role of
Nrf2 in thyroid homeostasis in mice and showed that genetic or phar-
macological activation of Nrf2, besides regulating an antioxidant pro-
gram in thyroid, can also directly activate the transcription of thyr-
oglobulin (Tg), the precursor protein of thyroid hormones, by binding
to two functional ARE sequences that are conserved between rodents
and human and reside in the distal enhancer region of the TG gene [9].
Next, to address the issue of potential thyroidal toxicity of cruciferous
vegetables preparations [10], we analyzed the serum of healthy vo-
lunteers who had ingested daily for 12 weeks a sulforaphane-rich
broccoli sprout extract as part of a previous study [11]; we observed no
adverse eﬀect on thyroidal function, as assessed by thyroid function
tests and thyroid autoantibody levels [12].
Based on these studies, we wondered whether genetic variation in
the Nrf2 pathway among humans, in the form of either common single-
nucleotide polymorphisms (SNPs) or rare mutations, could impact the
expression of Tg and/or its circulating levels in the serum. Regarding
common SNPs, we took advantage of the ﬁrst genome-wide association
study (GWAS) for Tg serum levels, which was performed in a Croatian
population and was recently published [13]. Speciﬁcally, we examined
whether SNPs in the KEAP1, NFE2L2 and CUL3 genes that had been
previously shown to be associated with other phenotypes or diseases
also had an impact on Tg levels. Regarding rare mutations, we focused
on a very rare SNP (rs778940395) in the proximal functional ARE of the
TG enhancer. The results identify common SNPs in the Nrf2 pathway
that are associated with the circulating levels of Tg; they also demon-
strate that the rare mutation in the TG completely inactivates its tran-
scriptional activity.
2. Materials and methods
2.1. Study population and SNPs
The list of SNPs investigated in this study comprised all SNPs in the
KEAP1, NFE2L2 and CUL3 genes that had been previously shown to be
associated with other phenotypes or diseases. This list was compiled
from a literature review, including both review papers of this topic
[14,15], as well as original publications. These are cited in Tables 1 and
2; the references in these Tables are not exhaustive in terms of the as-
sociated diseases and phenotypes, because the criterion for inclusion of
a SNP was the presence of at least one disease or phenotype. The dbSNP
and ClinVar databases were also searched. Only germline SNPs asso-
ciated with a disease or phenotype were included; somatic mutations
were excluded.
The population that was checked for SNPs in the Nrf2 pathway
comes from two Croatian cohorts as previously described [13] within
the 10,001 Dalmatians project [16]. Analyses of the GWAS data were
performed in three groups: (i) a population without thyroid disease and
with normal thyroid function tests, comprising 1094 subjects; this is the
population that has been previously published [13]; (ii) a population
with thyroid disease and/or abnormal thyroid function tests, com-
prising 815 subjects; and (iii) the above two groups combined, com-
prising 1909 subjects and considered as a general population. The
analyses of the GWAS data for the healthy subpopulation have been
previously described [13]; for the present work, the data from the
general population and thyroid population were also analyzed, in the
same manner as previously reported [13]. Thyroid disease and/or
Table 1
SNPs in NFE2L2, KEAP1 and CUL3 associated with various human diseases or phenotypes and with Tg levels.
Gene SNP p-value Tg* Location Functionality Disease/Phenotype**
NFE2L2 rs6706649 G: 0.0197
H: 0.086
D: 0.131
↓, allele T NC_000002.11:g.178130071C > T 2 kb upstream
variant
High cholesterol [31], ulcerative colitis [32] ,
maternal acetaminophen and asthma [33], PD [34],
ALS [35]
KEAP1 rs11668429 G: 0.086
H: 0.016
D: 0.737
↑, allele G NC_000019.9:g.10616303 T > G promoter Childhood asthma [36]
KEAP1 rs9676881 G: 0.173
H: 0.027
D: 0.864
↑, allele A NC_000019.9:g.10596780G > A 0.5 kb downstream
variant
COPD [37], diabetes [38]
KEAP1 rs1048290 G: 0.197
H: 0.03
D: 0.92
↑, allele C NC_000019.9:g.10600442G > C;
NM_012289.3:c.1413C > G (p.Leu471= )
exon 4
synonymous
variant
Renal protection against cisplatin [39], temporal
lobe epilepsy and drug-resistant epilepsy [40],
diabetes [38], cognitive impairment [41], breast
cancer [24]
For the SNPs that are within transcripts, both the mRNA (NM) and genomic (NC) references are given. Note that the minor allele always refers to the genomic
reference (NC). G: general population; H: healthy subpopulation (without any history, sign, or laboratory indication of thyroid disease); D: subpopulation with a
history, sign, or laboratory abnormality indicative of thyroid disease” (i.e., thyroid medication, thyroidectomy, thyroid autoimmunity, or levels of TSH, free T4, free
T3 and/or Tg outside the respective reference range). ALS: amyotrophic lateral sclerosis; COPD: chronic obstructive pulmonary disease; PD: Parkinson’s disease. *
Eﬀect of the indicated minor allele on Tg levels. ↑: increase; ↓: decrease. ** Known disease/phenotype associations of the respective SNP. All SNPs with at least one
reported association are listed, but not all references are necessarily cited for each SNPs).
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abnormal thyroid function tests were deﬁned as: thyroid medication
use, history of thyroid surgery, history of thyroid disorders, or thyroid
function tests levels out of the reference range (the parameters assessed
were TSH, free T4, free T3, Tg, Tg autoantibodies and thyroid perox-
idase autoantibodies). The study was approved by the Research Ethics
Committees in Croatia and Scotland, and all subjects gave written in-
formed consent. The analyses of the GWAS data for general population
and the healthy subpopulation have been previously described; for the
present work, the data from the thyroid population were also analyzed,
in the same manner as previously reported [13].
2.2. Blood chemistries
Concentrations of thyroid hormones, Tg and autoantibodies were
measured by immunoassay methods with the Liaison XL Biomedica
Chemiluminescence Analyzer (DiaSorin, Saluggia, Italy) as previously
described [13]. Measurements were performed in the Biochemistry
Laboratory in the Department of Nuclear Medicine at the University
Hospital of Split.
2.3. Plasmids construction
An already available luciferase reporter vector, hTGenh/prm-Luc
[17], containing the human TG upstream enhancer [18] and proximal
promoter [19] cloned upstream of the luciferase reporter gene of the
PGL3 vector (hereafter, pTg) was used to study the eﬀect of the
rs778940395 rare polymorphism. The pTg vector was used as a tem-
plate to create a reporter bearing the rs778940395 using the Quik-
Change II Site-Directed Mutagenesis Kit (Stratagene, San Diego, CA)
according to the manufacturer’s protocol. The following primers were
used for the in vitro mutagenesis: pTG-rs_F: 5′-CCTGTGTGCTGAATCT
TTCTTGCTGGCCTGG-3′; pTG-rs_R: 5′-CCAGGCCAGCAAGAAAGATTC
AGCACACAGG-3′. A previously created pTg enhancer/promoter con-
struct bearing a mutant proximal ARE sequence (MUT) [9] was used as
a positive control. All promoters constructs were veriﬁed by Sanger
sequencing. In order to exclude any artifact arising from plasmid iso-
lation of the WT and MUT constructs, two independent plasmid pre-
parations (clones) were used in the experiments.
2.4. Cell culture
PCCL3 cells, a clonal rat thyroid follicular cell line [20], were cul-
tured in Coon’s modiﬁed Ham’s F-12 under conditions described pre-
viously [9]. Culture media, supplements, sulforaphane and bovine TSH
were all from Sigma-Aldrich (St. Louis, MO). Generation of a Nrf2
knockout PCCL3 cell line using CRISPR/Cas9 technology has been
previously described [9]. PCCL3 cells were transiently transfected with
the diﬀerent pTg reporter constructs in 96-well plates in complete
medium using a 1:2 ratio of DNA and jetPRIME transfection reagent
(Polyplus-transfection, Illkirch, France) respectively. The pEGFP-N1
plasmid (Clontech, Mountain View, CA) was included in all transfection
experiments to monitor transfection eﬃciency and to normalize luci-
ferase activities [21]. Treatment with sulforaphane (5 µM) or vehicle
(DMSO) was performed 24 h after transfection. For TSH treatment, as
soon as 24 h had passed after transfection, cells were starved for 48 h
and then were treated with 0.5mIU/mL of TSH for 24 h. The starvation
medium (4H medium) contained 0.2% FBS and four of the six hormones
from the 6H medium [9] (TSH and insulin were excluded). Passive Lysis
Buﬀer (Promega, Madison, WI) was used to lyse the cells 48 h after
transfection and GFP ﬂuorescence was measured using a NOVOstar
multi–mode reader (BMG Labtech, Ortenberg, Germany) with excita-
tion and emission wavelengths of 480 and 520 nm, respectively. The
GFP ﬂuorescence background of non-transfected cells was used to blank
the ﬂuorescence measurements. Then, luciferase activities were mea-
sured in the same plate using the Luciferase Assay System (Promega)
according to the manufacturer's protocol. Luciferase activities were
normalized to GFP ﬂuorescence and relative luciferase activities were
expressed as fold change over control.
2.5. Statistics
Analyses of the GWAS data were performed as previously described
in detail [13]. Brieﬂy, Tg levels were adjusted for age and sex using
linear regression analysis and then derived residuals were inverse
normal-transformed and included in the linear mixed model, which
accounts for population structure and relatedness. “SNPTEST” and R
software were used to identify independently associated SNPs. Even
through the data examined were derived from a GWAS, the present
study took a hypothesis-based approach, wherein only a small set of
SNPs was investigated; the statistical threshold applied was thus a p-
value< 0.05.
In the cell-based studies, the normalized luciferase ratios were
analyzed using the BootstRatio application (http://rht.iconcologia.net/
stats/br/index.html). This software tool is based on bootstrapping and
resampling methods, without any assumption on the underlying prob-
ability distribution for the data analyzed [22]. The graphs were pre-
pared using GraphPad Prism v7 (GraphPad Software, Inc., La Jolla, CA).
3. Results
3.1. SNPs in KEAP1 and NFE2L2 genes are associated with circulating Tg
levels
Several SNPs in NFE2L2 have been previously associated with var-
ious human diseases and/or phenotypes (Tables 1 and 2). Among them
are especially three functional SNPs in the promoter of NFE2L2 itself
(rs35652124, rs6706649 and rs6721961), which have been shown to
regulate its transcriptional activity with the minor alleles leading to
reduced transcription [23]. Table 1 lists the SNPs with statistically
signiﬁcant p-values in the GWAS data in at least one population (gen-
eral population, health subpopulation or thyroid disease subpopula-
tion).
For NFE2L2, only rs6706649 was signiﬁcantly associated with Tg
levels, and only in the general population (p=0.0197). The minor
allele was associated with lower Tg levels. This is consistent with the
fact that rs6706649 is one of the three functional SNPs in the NFE2L2
promoter [23], and our previous ﬁnding that Nrf2 has a positive impact
on the transcription of the gene encoding Tg and the thyroidal levels of
Tg protein [9].
For KEAP1, three SNPs were signiﬁcantly associated with Tg levels,
all of them in the healthy population only (rs11668429, p=0.016;
rs9676881, p= 0.027; rs1048290, p=0.03). For all three, the minor
alleles were associated with higher Tg levels. Since it is not known
whether each of these three speciﬁc SNPs aﬀects KEAP1 expression, it is
not possible to comment whether the observed directional eﬀect (minor
alleles associated with higher Tg levels) is compatible with the afore-
mentioned positive eﬀect of Nrf2 signaling on Tg [9]. Nevertheless, the
fact all three minor alleles signiﬁcantly aﬀect Tg levels in the same
direction (increase) is consistent with the fact that these three SNPs are
in tight linkage disequilibrium with each other, as shown by the present
data and previous work [24].
Only one SNP in the CUL3 gene has been previously reported to be
associated with a human disease or phenotype (rs2396092, associated
with esophageal squamous cell carcinoma [25]. This SNP was not as-
sociated with Tg levels in the present study (Table 2).
3.2. One of the functional Nrf2 binding sites (ARE) on TG regulating region
harbors a very rare sequence variant.
The two binding sequences through which Nrf2 upregulates TG gene
transcription, ARE1 and ARE2, are located 2.8 kb and 3.2 kb, respec-
tively, upstream of the transcription initiation site [9]. According to the
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information currently available in the Database of Single Nucleotide
Polymorphisms (dbSNP build 152), ARE1 harbors a very rare sequence
variant, rs778940395 (NC_000008.11:g.132864133 T > A; frequency:
1/30958 in GnomAD; 1/3854 in ALSPAC; 0/3708 in TWINSUK)
(Fig. 1A). As there are no published studies on this variant, we in-
vestigated its functionality in cell-based reporter gene after introducing
it in the pTg promoter/enhancer luciferase reporter construct using in
vitro mutagenesis as described above (Fig. 1B) [9].
3.3. The rs778940395 variant in the TG distal enhancer is a completely
loss-of-function in terms of transcription activity
PCCL3 rat thyroid follicular cells were transfected with diﬀerent
plasmids: two clones that carry the wild-type ARE1 sequence (WT1 and
WT2, positive controls); two clones that carry the rs778940395 variant
(rs1 and rs2); or a previously generated mutant ARE1 version that we
have shown to be completely inactivating (MUT, positive control) [9]
(Fig. 1B). Both rs1 and r2 showed signiﬁcantly reduced ARE-driven
luciferase activity at baseline as compared to WT1 (which was itself not
diﬀerent from WT2); their activity levels were in fact not diﬀerent from
those of the MUT clone (Fig. 2A). These results indicate that the
rs778940395 variant abolishes the basal transcriptional activity of
ARE1. Treatment with sulforaphane signiﬁcantly induced ARE-driven
luciferase activity of the TG enhancer in the WT1 and WT2 clones, but
this induction was blunted in the rs1 and rs2 clones, again to a similar
extent as in the MUT clone (Fig. 2A). These results indicate that the
rs778940395 variant also abolishes the sulforaphane-inducible tran-
scriptional activity of ARE1. The same experiment was repeated in Nrf2
knockout PCCL3 cells engineered by CRISPR/Cas9 technology. In the
absence of Nrf2, no diﬀerences were observed either under basal con-
ditions or in response to sulforaphane treatment in any of the clones
(Fig. 2B). These data indicate that all the observed diﬀerences in
Fig. 2A are Nrf2-dependent; thus, the rs778940395 variant abolishes
the Nrf2-dependent transcriptional activity of ARE1, both the basal one
and the sulforaphane-inducible one.
We have shown previously that Nrf2 mediates the induction of the
TG promoter not only by sulforaphane but also by TSH [9]. We there-
fore repeated the experiment in PCCL3 WT cells and treated them with
TSH, as described in the Methods. As expected, TSH induced ~2.5-fold
the ARE-driven luciferase activity in WT1 and WT2 (Fig. 2C). The rs1
Fig. 1. The distal enhancer of TG harbors a
rare SNP in one of its functional Nrf2
binding sites (AREs). A. rs778940395,
T > A is located in the core sequence of one
of the two AREs in the TG enhancer. The
core ARE sequence is indicated in grey. The
nucleotide base that changes is indicated in
red. B. Plasmid constructs that express luci-
ferase under the control of the TG promoter/
enhancer used in the present study. The ﬁrst
construct carries the wild-type (WT) core
proximal ARE sequence (ARE1). In the
second construct, SNP rs778940395 was
introduced in ARE1 by in vitro mutagenesis.
The third construct (MUT) carries an ARE1
modiﬁed by in vitro mutagenesis that has been previously shown to be completely inactive. Binding sites for thyroid transcription factor 1 (TTF1) and a cAMP
response element (CRE)-like potential binding site are also indicated.
Fig. 2. The rare variant rs778940395 in the proximal ARE of the TG distal enhancer leads to complete loss of basal and inducible transcriptional activity. A.
Introduction of rs778940395 abrogates the basal and sulforaphane-induced ARE1-driven TG promoter/enhancer luciferase activity. PCCL3 wild-type (WT) cells were
cultured in complete medium in 96-well plates and were transfected with diﬀerent TG promoter/enhancer luciferase reporter constructs. Speciﬁcally, two clones with
wild-type (WT1 and WT2) proximal AREs, two clones carrying rs778940395 in ARE1 (rs1, rs2) and a previously validated mutant ARE1 clone were used (MUT). After
24 h, cells were treated with 5 µM sulforaphane (_SLF) or vehicle (< 0.1% dimethyl sulfoxide) as control (_C); 24 h later, cells were lysed and luciferase activity was
measured. Each column represents the mean ± SD of 7 independent experiments. *p < 0.05 vs. WT1_C; $p < 0.05 vs. WT1_SLF; #p < 0.05 vs. MUT_C; ‡p < 0.05
vs. MUT_SLF. B. Deletion of Nrf2 abrogates all changes in the ARE-driven TG promoter/enhancer luciferase activity induced by ARE1 mutation or sulforaphane
treatment. The same experiment illustrated in A was performed in Nrf2 knockout (Nrf2KO) PCCL3 cells developed by Crispr/CAS9 technology. In the absence of Nrf2,
the activity of the TG promoter/enhancer is unaﬀected by the presence or absence of rs77894039 as well as by treatment with sulforaphane. Each column represents
the mean ± SD of 7 independent experiments. C. Introduction of rs778940395 to the TG promoter/enhancer blunts its TSH-induced activity, behaving like the
complete loss-of-function mutant ARE version. 24 h after transfection, WT PCCL3 cells were starved in 4H medium (medium without TSH and insulin) supplemented
with 0.2% FBS for 48 h, and then they were treated or not with TSH (0.5 mU/ml) for 24 h. Each column represents the mean ± SD of 7 independent experiments.
*p < 0.05 vs. WT1_C; $p < 0.05 vs. WT1_TSH, #p < 0.05 vs. MUT_C, ‡p < 0.05 vs. MUT_TSH.
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and rs2 clones showed signiﬁcantly lower inducibility (~1.5-fold),
which was again not diﬀerent from that of the MUT clone (Fig. 2C).
These results indicate that the rs778940395 variant also abolishes the
TSH-inducible transcriptional activity of ARE1.
4. Discussion
Nrf2 is a proven druggable target for chemoprevention by natural
antioxidants, and compounds like sulforaphane have been used in
clinical trials in a variety of disease settings [26,27]. The emerging links
between Nrf2 and the thyroid gland suggest that further research is
warranted to better understand, and potentially also predict, whether
pharmacological manipulation of Nrf2 can impact thyroid physiology
or pathophysiology in a beneﬁcial or detrimental manner, whether it is
neutral, or whether genetic factors can act as determinants of this re-
lationship. Indeed, human genetic studies indicate that potent activa-
tion of Nrf2 signaling throughout life can be detrimental for the thyroid;
this conclusion is drawn from the fact that two published case reports
on unrelated families from Japan have associated two diﬀerent germ-
line loss-of-functions mutations in KEAP1 with familial multinodular
goiter inherited in an autosomal dominant manner [28,29]. However,
these are very rare mutations, which can be actually considered “pri-
vate”, since each of them has been documented only in a single family;
thus, the relevance for the general population remains unknown.
To the best of our knowledge, the present study is the ﬁrst one to
explore the impact on the thyroid of inherited genetic variation in the
Keap1/Nrf2 pathway by focusing on variants that are likely to lead to
much more mild alterations of the pathway’s activity. The SNPs in-
cluded in the GWAS analyses are classiﬁed as common variants, which,
when associated with diseases or phenotypes, usually have small eﬀect
sizes. The results indicate that common genetic variation in NFE2L2 or
KEAP1 is indeed associated with circulating Tg levels in the general
population or in the healthy subpopulation, respectively. Regarding the
molecular mechanism by which the SNPs aﬀect Tg levels, because
rs6706649 is known to be associated with lower NFE2L2 expression in
in vitro studies [23], we postulate that this leads to lower basal levels
and lower activity of Nrf2, thereby causing decreased ARE-driven TG
gene transcription and ultimately decreased Tg circulating levels. We
acknowledge that this is a hypothesis, as we do not have direct mea-
sures of NFE2L2 expression or Nrf2 activity in the thyroid gland of these
subjects (this is a general limitation of association studies of the NFE2L2
functional SNPs). For the KEAP1 SNPs rs11668429, rs9676881 and
rs1048290, we postulate that the observed eﬀects on Tg levels are also
likely mediated by altered Nrf2 activity; however, as noted in the Re-
sults, there are no published data on whether these three speciﬁc SNPs
aﬀect KEAP1 expression. No associations were found in the sub-
population with documented or suspected thyroid disease. One likely
explanation is that thyroid disease per se or the existence of anti-Tg
antibodies can induce substantial changes in the serum Tg levels or its
measurement results, respectively, that obscure any mild impact of
genetic variations in the Nrf2 pathway. Another explanation, not mu-
tually exclusive with the aforementioned one, may be that mild impact
of the common SNPs on Tg levels is not suﬃcient to cause thyroid
disease. This is consistent with our recent clinical study that found no
negative impact on thyroid hormonal or autoimmune status of a sul-
foraphane-containing beverage ingested over 12 weeks [12]. Taken
together, these ﬁndings support the notion that, in contrast to potent
and continuous activation of Nrf2 by loss-of-function mutations in
KEAP1, mild or time-restricted alteration of Nrf2 pathway activity is
more likely to be well tolerated by the thyroid.
Unlike the common SNPs interrogated in the GWAS, rs778940395 is
very rare. Nevertheless, similar to the common SNPs, it can also be
reasonably expected to have an overall mild eﬀect at the molecular
level. This is because, due to its rarity, it is highly unlikely to be en-
countered in the homozygous state. We hypothesize that rs778940395
abolishes the DNA binding of Nrf2, which we have previously shown to
bind directly to the wild-type ARE1 [9]. Even though the mutant ARE1
has no transcriptional activity, a subject heterozygous for rs778940395
would still normally possess three functional AREs in his/her distal Tg
enhancer, i.e., the ARE1 on the wild-type allele plus the two wild-type
ARE2s. Hence, it can be estimated that rs778940395 would lower Tg
mRNA levels by 25%. Even though ARE2 also regulates positively the
basal and inducible activity of the TG enhancer [9], it does not harbor
any SNPs, and thus the present analyses focused on the polymorphic
ARE1.
One limitation of the present study is that, due to the rarity of
rs778940395, we were not able to have access to carriers of this SNPs in
order to document whether they have a thyroidal phenotype or not.
Therefore, we believe that it is important to make these functional data
publicly available, in order to motivate the identiﬁcation and thyroidal
phenotyping of carriers of this rare variant, possibly in the context of
high-scale genotyping eﬀorts like the 100′000 genomes project [30]. In
the same spirit, we acknowledge that the “non-healthy” subpopulation
analyzed in the present study was not homogeneous in terms of the
underlying thyroid disease or thyroid function test abnormality. We
therefore suggest that studies are thus warranted to examine the genetic
association of SNPs in the Nrf2 pathway with speciﬁc thyroid diseases.
In conclusion, the present study demonstrates that both rare and
common genetic variation in the Keap1/Nrf2 pathway can impact TG
expression and Tg circulating levels, respectively, and it sets the stage
for follow-up studies that will characterize associations of genetic var-
iants in the pathway with speciﬁc thyroid diseases. Such studies are
useful to predict the impact of pharmacological manipulation of Nrf2
on the thyroid and the underlying mechanisms, and they are com-
plementary to clinical pharmacological studies with compounds that
activate or inhibit Nrf2, of which the natural antioxidant sulforaphane
serves as a prototype.
Acknowledgments
This work was supported by two Short Term Scientiﬁc Missions by
European Cooperation in Science and Technology Action CA16112
“NutRedOx – Personalized nutrition in aging society: redox control of
major age-related diseases” [to D.V.C. and G.P.S.]; Swiss National
Science Fund SNF-COST projects C15.0045-174626 and IZCOZ0-
177070 [to G.P.S.]; Swiss National Science Fund project
31003A_182105 [to G.P.S.]; a Swiss Society for Endocrinology-
Diabetology 2014 Young Independent Investigator Award [to G.P.S.]);
a Leenaards Foundation 2016 Fellowship for Academic Promotion in
Clinical Medicine [to G.P.S.]; a “3E-Exchange in Endocrinology
Expertise fellowship” by Section/Board of Endocrinology of the UEMS
[to D.V.C.]; and The Croatian Science Foundation project
“Identiﬁcation of new genetic loci implicated in regulation of thyroid
and parathyroid function” (grant no. 1498) [to T.Z].
No conﬂicts of interest were reported by all authors.
References
[1] M. Yamamoto, T.W. Kensler, H. Motohashi, The KEAP1-NRF2 system: a thiol-based
sensor-eﬀector apparatus for maintaining redox homeostasis, Physiol. Rev. 98 (3)
(2018) 1169–1203.
[2] T. Iso, T. Suzuki, L. Baird, M. Yamamoto, Absolute amounts and status of the Nrf2-
Keap1-Cul3 complex within cells, Mol. Cell. Biol. 36 (24) (2016) 3100–3112.
[3] A.T. Dinkova-Kostova, P. Talalay, Direct and indirect antioxidant properties of in-
ducers of cytoprotective proteins, Mol. Nutr. Food Res. 52 (Suppl. 1) (2008)
S128–S138.
[4] K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi,
K. Satoh, I. Hatayama, M. Yamamoto, Y. Nabeshima, An Nrf2/small Maf hetero-
dimer mediates the induction of phase II detoxifying enzyme genes through anti-
oxidant response elements, Biochem. Biophys. Res. Commun. 236 (2) (1997)
313–322.
[5] J.W. Fahey, S.L. Wehage, W.D. Holtzclaw, T.W. Kensler, P.A. Egner, T.A. Shapiro,
P. Talalay, Protection of humans by plant glucosinolates: eﬃciency of conversion of
glucosinolates to isothiocyanates by the gastrointestinal microﬂora, Cancer Prev
Res (Phila) 5 (4) (2012) 603–611.
[6] D.L. Palliyaguru, J.M. Yuan, T.W. Kensler, J.W. Fahey, Isothiocyanates: translating
A. Matana, et al. Biochemical Pharmacology xxx (xxxx) xxx–xxx
7
the power of plants to people, Mol. Nutr. Food Res. 62 (18) (2018) e1700965.
[7] A.S. Axelsson, E. Tubbs, B. Mecham, S. Chacko, H.A. Nenonen, Y. Tang, J.W. Fahey,
J.M.J. Derry, C.B. Wollheim, N. Wierup, M.W. Haymond, S.H. Friend, H. Mulder,
A.H. Rosengren, Sulforaphane reduces hepatic glucose production and improves
glucose control in patients with type 2 diabetes, Sci. Transl. Med. 9 (394) (2017).
[8] A. Cuadrado, A.I. Rojo, G. Wells, J.D. Hayes, S.P. Cousin, W.L. Rumsey,
O.C. Attucks, S. Franklin, A.L. Levonen, T.W. Kensler, A.T. Dinkova-Kostova,
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Nat.
Rev. Drug Discov. 18 (4) (2019) 295–317.
[9] P.G. Ziros, I.G. Habeos, D.V. Chartoumpekis, E. Ntalampyra, E. Somm, C.O. Renaud,
M. Bongiovanni, I.P. Trougakos, M. Yamamoto, T.W. Kensler, P. Santisteban,
N. Carrasco, C. Ris-Stalpers, E. Amendola, X.H. Liao, L. Rossich, L. Thomasz,
G.J. Juvenal, S. Refetoﬀ, G.P. Sykiotis, NFE2-related transcription factor 2 co-
ordinates antioxidant defense with thyroglobulin production and iodination in the
thyroid gland, Thyroid 28 (6) (2018) 780–798.
[10] P. Felker, R. Bunch, A.M. Leung, Concentrations of thiocyanate and goitrin in
human plasma, their precursor concentrations in brassica vegetables, and asso-
ciated potential risk for hypothyroidism, Nutr. Rev. 74 (4) (2016) 248–258.
[11] P.A. Egner, J.G. Chen, A.T. Zarth, D.K. Ng, J.B. Wang, K.H. Kensler, L.P. Jacobson,
A. Munoz, J.L. Johnson, J.D. Groopman, J.W. Fahey, P. Talalay, J. Zhu, T.Y. Chen,
G.S. Qian, S.G. Carmella, S.S. Hecht, T.W. Kensler, Rapid and sustainable detox-
ication of airborne pollutants by broccoli sprout beverage: results of a randomized
clinical trial in China, Cancer Prev. Res. (Phila) 7 (8) (2014) 813–823.
[12] D.V. Chartoumpekis, P.G. Ziros, J.G. Chen, J.D. Groopman, T.W. Kensler,
G.P. Sykiotis, Broccoli sprout beverage is safe for thyroid hormonal and auto-
immune status: Results of a 12-week randomized trial, Food Chem. Toxicol. 126
(2019) 1–6.
[13] A. Matana, M. Popovic, T. Boutin, V. Torlak, D. Brdar, I. Gunjaca, I. Kolcic,
V. Boraska Perica, A. Punda, I. Rudan, O. Polasek, M. Barbalic, C. Hayward,
T. Zemunik, Genetic variants in the ST6GAL1 gene are associated with thyr-
oglobulin plasma level in healthy individuals, Thyroid 29 (6) (2019) 886–893.
[14] H.Y. Cho, J. Marzec, S.R. Kleeberger, Functional polymorphisms in Nrf2: implica-
tions for human disease, Free Radic. Biol. Med. 88 (Pt. B) (2015) 362–372.
[15] U. Dhamodharan, B. Ponjayanthi, D. Sireesh, E. Bhakkiyalakshmi, K.M. Ramkumar,
Association of single-nucleotide polymorphisms of the KEAP1 gene with the risk of
various human diseases and its functional impact using in silico analysis,
Pharmacol. Res. 137 (2018) 205–218.
[16] I. Rudan, A. Marusic, S. Jankovic, K. Rotim, M. Boban, G. Lauc, I. Grkovic, Z. Dogas,
T. Zemunik, Z. Vatavuk, G. Bencic, D. Rudan, R. Mulic, V. Krzelj, J. Terzic,
D. Stojanovic, D. Puntaric, E. Bilic, D. Ropac, A. Vorko-Jovic, A. Znaor,
R. Stevanovic, Z. Biloglav, O. Polasek, “10001 Dalmatians:” Croatia launches its
national biobank, Croat. Med. J. 50 (1) (2009) 4–6.
[17] J. Pohlenz, A. Dumitrescu, D. Zundel, U. Martine, W. Schonberger, E. Koo,
R.E. Weiss, R.N. Cohen, S. Kimura, S. Refetoﬀ, Partial deﬁciency of thyroid tran-
scription factor 1 produces predominantly neurological defects in humans and mice,
J. Clin. Invest. 109 (4) (2002) 469–473.
[18] V. Berg, G. Vassart, D. Christophe, Identiﬁcation of a thyroid-speciﬁc and cAMP-
responsive enhancer in the upstream sequences of the human thyroglobulin pro-
moter, BBA 1307 (1) (1996) 35–38.
[19] A. Donda, F. Javaux, P. Van Renterghem, C. Gervy-Decoster, G. Vassart,
D. Christophe, Human, bovine, canine and rat thyroglobulin promoter sequences
display species-speciﬁc diﬀerences in an in vitro study, Mol. Cell. Endocrinol. 90 (2)
(1993) R23–R26.
[20] A. Fusco, M.T. Berlingieri, P.P. Di Fiore, G. Portella, M. Grieco, G. Vecchio, One-
and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes,
Mol. Cell. Biol. 7 (9) (1987) 3365–3370.
[21] D.H. Dandekar, M. Kumar, J.S. Ladha, K.N. Ganesh, D. Mitra, A quantitative method
for normalization of transfection eﬃciency using enhanced green ﬂuorescent pro-
tein, Anal. Biochem. 342 (2) (2005) 341–344.
[22] R. Cleries, J. Galvez, M. Espino, J. Ribes, V. Nunes, M.L. de Heredia, BootstRatio: A
web-based statistical analysis of fold-change in qPCR and RT-qPCR data using re-
sampling methods, Comput. Biol. Med. 42 (4) (2012) 438–445.
[23] C.C. Hua, L.C. Chang, J.C. Tseng, C.M. Chu, Y.C. Liu, W.B. Shieh, Functional hap-
lotypes in the promoter region of transcription factor Nrf2 in chronic obstructive
pulmonary disease, Dis. Markers 28 (3) (2010) 185–193.
[24] J.M. Hartikainen, M. Tengstrom, R. Winqvist, A. Jukkola-Vuorinen, K. Pylkas,
V.M. Kosma, Y. Soini, A. Mannermaa, KEAP1 genetic polymorphisms associate with
breast cancer risk and survival outcomes, Clin. Cancer Res. 21 (7) (2015)
1591–1601.
[25] J.L. Hu, X.L. Hu, C.X. Lu, X.J. Chen, L. Fu, Q. Han, S.D. Cang, Variants in the 3'-
untranslated region of CUL3 is associated with risk of esophageal squamous cell
carcinoma, J. Cancer 9 (20) (2018) 3647–3650.
[26] M.K. Kwak, T.W. Kensler, Targeting NRF2 signaling for cancer chemoprevention,
Toxicol. Appl. Pharmacol. 244 (1) (2010) 66–76.
[27] L. Yang, D.L. Palliyaguru, T.W. Kensler, Frugal chemoprevention: targeting Nrf2
with foods rich in sulforaphane, Semin. Oncol. 43 (1) (2016) 146–153.
[28] R. Teshiba, T. Tajiri, K. Sumitomo, K. Masumoto, T. Taguchi, K. Yamamoto,
Identiﬁcation of a KEAP1 germline mutation in a family with multinodular goitre,
PLoS One 8 (5) (2013) e65141.
[29] E. Nishihara, A. Hishinuma, T. Kogai, N. Takada, M. Hirokawa, S. Fukata, M. Ito,
T. Yabuta, M. Nishikawa, H. Nakamura, N. Amino, A. Miyauchi, A novel germline
mutation of KEAP1 (R483H) associated with a non-toxic multinodular goiter, Front.
Endocrinol. (Lausanne) 7 (2016) 131.
[30] M. Peplow, The 100,000 genomes project, BMJ 353 (2016) i1757.
[31] T. Kunnas, K. Maatta, S.T. Nikkari, Genetic polymorphisms of transcription factor
NRF2 and of its host gene sulﬁredoxin (SRXN1) are associated with cerebrovascular
disease in a ﬁnnish cohort, the TAMRISK Study, Int. J. Med. Sci. 13 (5) (2016)
325–329.
[32] T. Arisawa, T. Tahara, T. Shibata, M. Nagasaka, M. Nakamura, Y. Kamiya, H. Fujita,
D. Yoshioka, M. Okubo, M. Sakata, F.Y. Wang, I. Hirata, H. Nakano, Nrf2 gene
promoter polymorphism is associated with ulcerative colitis in a Japanese popu-
lation, Hepatogastroenterology 55 (82–83) (2008) 394–397.
[33] S.O. Shaheen, R.B. Newson, S.M. Ring, M.J. Rose-Zerilli, J.W. Holloway,
A.J. Henderson, Prenatal and infant acetaminophen exposure, antioxidant gene
polymorphisms, and childhood asthma, J. Allergy Clin. Immunol. 126 (6) (2010)
1141-8 e7.
[34] M. von Otter, S. Landgren, S. Nilsson, D. Celojevic, P. Bergstrom, A. Hakansson,
H. Nissbrandt, M. Drozdzik, M. Bialecka, M. Kurzawski, K. Blennow, M. Nilsson,
O. Hammarsten, H. Zetterberg, Association of Nrf2-encoding NFE2L2 haplotypes
with Parkinson’s disease, BMC Med. Genet. 11 (2010) 36.
[35] P. Bergstrom, M. von Otter, S. Nilsson, A.C. Nilsson, M. Nilsson, P.M. Andersen,
O. Hammarsten, H. Zetterberg, Association of NFE2L2 and KEAP1 haplotypes with
amyotrophic lateral sclerosis, Amyotroph Lateral Scler. Frontotemporal Degener. 15
(1–2) (2014) 130–137.
[36] I. Ungvari, E. Hadadi, V. Virag, A. Nagy, A. Kiss, A. Kalmar, G. Zsigmond,
A.F. Semsei, A. Falus, C. Szalai, Relationship between air pollution, NFE2L2 gene
polymorphisms and childhood asthma in a Hungarian population, J. Commun.
Genet. 3 (1) (2012) 25–33.
[37] M. Siedlinski, D.S. Postma, J.M. Boer, G. van der Steege, J.P. Schouten, H.A. Smit,
H.M. Boezen, Level and course of FEV1 in relation to polymorphisms in NFE2L2 and
KEAP1 in the general population, Respir. Res. 10 (2009) 73.
[38] H. Fukushima-Uesaka, Y. Saito, K. Maekawa, N. Kamatani, H. Kajio, N. Kuzuya,
M. Noda, K. Yasuda, J. Sawada, Genetic variations and haplotype structures of
transcriptional factor Nrf2 and its cytosolic reservoir protein Keap1 in Japanese,
Drug Metab. Pharmacokinet. 22 (3) (2007) 212–219.
[39] C. Chang, Y. Hu, S.L. Hogan, N. Mercke, M. Gomez, C. O'Bryant, D.W. Bowles,
B. George, X. Wen, L.M. Aleksunes, M.S. Joy, Pharmacogenomic variants may in-
ﬂuence the urinary excretion of novel kidney injury biomarkers in patients re-
ceiving cisplatin, Int. J. Mol. Sci. 18 (7) (2017).
[40] Z. Liu, X. Yin, L. Liu, H. Tao, H. Zhou, G. Ma, L. Cui, Y. Li, S. Zhang, Z. Xu, L. Yao,
Z. Cai, B. Zhao, K. Li, Association of KEAP1 and NFE2L2 polymorphisms with
temporal lobe epilepsy and drug resistant epilepsy, Gene 571 (2) (2015) 231–236.
[41] Y. Shirai, Y. Fujita, R. Hashimoto, K. Ohi, H. Yamamori, Y. Yasuda, T. Ishima,
H. Suganuma, Y. Ushida, M. Takeda, K. Hashimoto, Dietary intake of sulforaphane-
rich broccoli sprout extracts during juvenile and adolescence can prevent phency-
clidine-induced cognitive deﬁcits at adulthood, PLoS One 10 (6) (2015) e0127244.
[42] M. von Otter, S. Landgren, S. Nilsson, M. Zetterberg, D. Celojevic, P. Bergstrom,
L. Minthon, N. Bogdanovic, N. Andreasen, D.R. Gustafson, I. Skoog, A. Wallin,
G. Tasa, K. Blennow, M. Nilsson, O. Hammarsten, H. Zetterberg, Nrf2-encoding
NFE2L2 haplotypes inﬂuence disease progression but not risk in Alzheimer’s disease
and age-related cataract, Mech. Ageing Dev. 131 (2) (2010) 105–110.
[43] E.J. Cordova, R. Velazquez-Cruz, F. Centeno, V. Baca, L. Orozco, The NRF2 gene
variant,-653G/A, is associated with nephritis in childhood-onset systemic lupus
erythematosus, Lupus 19 (10) (2010) 1237–1242.
[44] C. Ran, K. Wirdefeldt, L. Brodin, M. Ramezani, M. Westerlund, F. Xiang, A. Anvret,
T. Willows, O. Sydow, A. Johansson, D. Galter, P. Svenningsson, A.C. Belin, Genetic
variations and mRNA expression of NRF2 in Parkinson’s disease, Parkinsons Dis-Us
(2017).
[45] T. Arisawa, T. Tahara, T. Shibata, M. Nagasaka, M. Nakamura, Y. Kamiya, H. Fujita,
S. Hasegawa, T. Takagi, F.Y. Wang, I. Hirata, H. Nakano, The relationship between
Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in
chronic gastritis, Int. J. Mol. Med. 19 (1) (2007) 143–148.
[46] T. Arisawa, T. Tahara, T. Shibata, M. Nagasaka, M. Nakamura, Y. Kamiya, H. Fujita,
D. Yoshioka, M. Okubo, I. Hirata, H. Nakano, Nrf2 gene promoter polymorphism
and gastric carcinogenesis, Hepatogastroenterology 55 (82–83) (2008) 750–754.
[47] P. Song, K. Li, L. Liu, X.W. Wang, Z. Jian, W.G. Zhang, G. Wang, C.Y. Li, T.W. Gao,
Genetic polymorphism of the Nrf2 promoter region is associated with vitiligo risk in
Han Chinese populations, J. Cell Mol. Med. 20 (10) (2016) 1840–1850.
[48] Y. Shimoyama, Y. Mitsuda, Y. Tsuruta, N. Hamajima, T. Niwa, Polymorphism of
Nrf2, an antioxidative gene, is associated with blood pressure and cardiovascular
mortality in hemodialysis patients, Int. J. Med. Sci. 11 (7) (2014) 726–731.
[49] E.D. Marczak, J. Marzec, D.C. Zeldin, S.R. Kleeberger, N.J. Brown, M. Pretorius,
C.R. Lee, Polymorphisms in the transcription factor NRF2 and forearm vasodilator
responses in humans, Pharmacogenet. Genom. 22 (8) (2012) 620–628.
[50] B.L. Yu, H.L. Lin, L.X. Yang, K. Chen, H.H. Luo, J.Q. Liu, X.C. Gao, X.F. Xia,
Z.F. Huang, Genetic variation in the Nrf2 promoter associates with defective sper-
matogenesis in humans, J. Mol. Med. 90 (11) (2012) 1333–1342.
[51] J. Bouligand, O. Cabaret, M. Canonico, C. Verstuyft, L. Dubert, L. Becquemont,
A. Guiochon-Mantel, P.Y. Scarabin, E.T. Risk, Eﬀect of NFE2L2 genetic poly-
morphism on the association between oral estrogen therapy and the risk of venous
thromboembolism in postmenopausal women, Clin. Pharmacol. Ther. 89 (1) (2011)
60–64.
[52] M. Acosta-Herrera, M. Pino-Yanes, J. Blanco, J.C. Ballesteros, A. Ambros,
A. Corrales, F. Gandia, C. Subira, D. Dominguez, A. Baluja, J.M. Anon, R. Adalia,
L. Perez-Mendez, C. Flores, J. Villar, G. Network, G.-S. Network, Common variants
of NFE2L2 gene predisposes to acute respiratory distress syndrome in patients with
severe sepsis, Crit. Care 19 (2015).
[53] J.M. Marzec, J.D. Christie, S.P. Reddy, A.E. Jedlicka, H. Vuong, P.N. Lanken,
R. Aplenc, T. Yamamoto, M. Yamamoto, H.Y. Cho, S.R. Kleeberger, Functional
polymorphisms in the transcription factor NRF2 in humans increase the risk of
acute lung injury, FASEB J. 21 (9) (2007) 2237–2246.
[54] D.S. O'Mahony, B.J. Glavan, T.D. Holden, C. Fong, R.A. Black, G. Rona, P. Tejera,
A. Matana, et al. Biochemical Pharmacology xxx (xxxx) xxx–xxx
8
D.C. Christiani, M.M. Wurfel, Inﬂammation and immune-related candidate gene
associations with acute lung injury susceptibility and severity: a validation study,
PLoS One 7 (12) (2012) e51104.
[55] A.S. Jimenez-Osorio, S. Gonzalez-Reyes, W.R. Garcia-Nino, H. Moreno-Macias,
M.E. Rodriguez-Arellano, G. Vargas-Alarcon, J. Zuniga, R. Barquera, J. Pedraza-
Chaverri, Association of nuclear factor-erythroid 2-related factor 2, thioredoxin
interacting protein, and heme oxygenase-1 gene polymorphisms with diabetes and
obesity in mexican patients, Oxid. Med. Cell. Longev. (2016).
[56] V. Sampath, J.S. Garland, D. Helbling, D. Dimmock, N.P. Mulrooney, P.M. Simpson,
J.C. Murray, J.M. Dagle, Antioxidant response genes sequence variants and BPD
susceptibility in VLBW infants, Pediatr. Res. 77 (3) (2015) 477–483.
[57] B.L. Yu, J.Y. Chen, D. Liu, H. Zhou, W.W. Xiao, X.F. Xia, Z.F. Huang, Cigarette
smoking is associated with human semen quality in synergy with functional NRF2
polymorphisms, Biol. Reprod. 89 (1) (2013).
[58] Y. Okano, U. Nezu, Y. Enokida, M.T.M. Lee, H. Kinoshita, A. Lezhava,
Y. Hayashizaki, S. Morita, M. Taguri, Y. Ichikawa, T. Kaneko, Y. Natsumeda,
T. Yokose, H. Nakayama, Y. Miyagi, T. Ishikawa, SNP (-617C>A) in ARE-Like Loci
of the NRF2 Gene: a new biomarker for prognosis of lung adenocarcinoma in
Japanese non-smoking women, PLoS One 8 (9) (2013).
[59] H. Masuko, T. Sakamoto, Y. Kaneko, H. Iijima, T. Naito, E. Noguchi, T. Hirota,
M. Tamari, N. Hizawa, An interaction between Nrf2 polymorphisms and smoking
status aﬀects annual decline in FEV1: a longitudinal retrospective cohort study,
BMC Med. Genet. 12 (2011).
[60] S.M. Figarska, J.M. Vonk, H.M. Boezen, NFE2L2 polymorphisms, mortality, and
metabolism in the general population, Physiol. Genomics 46 (12) (2014) 411–417.
[61] H. Masuko, T. Sakamoto, Y. Kaneko, H. Iijima, T. Naito, E. Noguchi, T. Hirota,
M. Tamari, N. Hizawa, Lower FEV1 in non-COPD, nonasthmatic subjects: associa-
tion with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes,
Int. J. Chronic. Obstr. 6 (2011) 181–189.
[62] C. Canova, C. Dunster, F.J. Kelly, C. Minelli, P.L. Shah, C. Caneja, M.K. Tumilty,
P. Burney, PM10-induced hospital admissions for asthma and chronic obstructive
pulmonary disease the modifying eﬀect of individual characteristics, Epidemiology
23 (4) (2012) 607–615.
[63] B.J. Wang, M.J. Liu, W.H. Yan, J. Mao, D. Jiang, H. Li, Y. Chen, Association of SNPs
in genes involved in folate metabolism with the risk of congenital heart disease, J.
Matern-Fetal Neo. M 26 (18) (2013) 1768–1777.
[64] T. Khunluck, V. Kukongviriyapan, A. Puapairoj, N. Khuntikeo, L. Senggunprai,
P. Zeekpudsa, A. Prawan, Association of NRF2 polymorphism with cholangio-
carcinoma prognosis in Thai patients, Asian Pac. J. Cancer P 15 (1) (2014)
298–303.
[65] E. Synowiec, T. Sliwinski, K. Danisz, J. Blasiak, A. Sklodowska, D. Romaniuk,
C. Watala, J. Szaﬂik, J.P. Szaﬂik, Association between polymorphism of the NQO1,
NOS3 and NFE2L2 genes and AMD, Front. Biosci-Landmrk 18 (2013) 80–90.
[66] M. Todorovic, J.R.B. Newman, J.G. Shan, S. Bentley, S.A. Wood, P.A. Silburn,
G.D. Mellick, Comprehensive assessment of genetic sequence variants in the anti-
oxidant ‘master regulator' Nrf2 in idiopathic Parkinson’s disease, PLoS One 10 (5)
(2015).
[67] P. Huppke, S. Weissbach, J.A. Church, R. Schnur, M. Krusen, S. Dreha-Kulaczewski,
W.N. Kuhn-Velten, A. Wolf, B. Huppke, F. Millan, A. Begtrup, F. Almusafri,
H. Thiele, J. Altmuller, P. Nurnberg, M. Muller, J. Gartner, Activating de novo
mutations in NFE2L2 encoding NRF2 cause a multisystem disorder, Nat. Commun.
8 (1) (2017) 818.
[68] J. Yeo, D.A. Morales, T. Chen, E.L. Crawford, X.L. Zhang, T.M. Blomquist,
A.M. Levin, P.P. Massion, D.A. Arenberg, D.E. Midthun, P.J. Mazzone, S.D. Nathan,
R.J. Wainz, P. Nana-Sinkam, P.F.S. Willey, T.J. Arend, K. Padda, S.H. Qiu,
A. Federov, D.A.R. Hernandez, J.R. Hammersley, Y. Yoon, F. Saﬁ, S.A. Khuder,
J.C. Willey, RNAseq analysis of bronchial epithelial cells to identify COPD-asso-
ciated genes and SNPs, BMC Pulm. Med. 18 (2018).
A. Matana, et al. Biochemical Pharmacology xxx (xxxx) xxx–xxx
9
